On the public citation graph
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management
0 signed · 496 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ajh.24615openalex-snapshot
Diffuse large B‐cell lymphoma with primary treatment failure: Ultra‐high risk features and benchmarking for experimental therapies
inferredcites →https://doi.org/10.1002/hon.1017openalex-snapshot
Cell of origin fails to predict survival in patients with diffuse large B‐cell lymphoma treated with autologous hematopoietic stem cell transplantation
inferredcites →https://doi.org/10.1002/hon.7_2632openalex-snapshot
PORTIA: A PHASE 1B STUDY EVALUATING SAFETY AND EFFICACY OF TISAGENLECLEUCEL AND PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
inferredcites →https://doi.org/10.1016/s0140-6736(13)60313-xopenalex-snapshot
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
inferredcites →https://doi.org/10.1016/s0140-6736(19)33008-9openalex-snapshot
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
inferredcites →https://doi.org/10.1016/s0140-6736(20)31366-0openalex-snapshot
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
inferredcites →https://doi.org/10.1016/s1470-2045(12)70481-3openalex-snapshot
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)
inferredcites →https://doi.org/10.1016/s1470-2045(15)70106-3openalex-snapshot
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
inferredcites →https://doi.org/10.1016/s1470-2045(20)30225-4openalex-snapshot
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
inferredcites →https://doi.org/10.1016/s2352-3026(18)30177-7openalex-snapshot
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study
inferredcites →https://doi.org/10.1016/s2352-3026(20)30120-4openalex-snapshot
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
inferredcites →https://doi.org/10.1038/35000501openalex-snapshot
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
inferredcites →https://doi.org/10.1038/bmt.2015.213openalex-snapshot
Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
inferredcites →https://doi.org/10.1038/s41571-021-00470-8openalex-snapshot
Unlocking the potential of antibody–drug conjugates for cancer therapy
inferredcites →https://doi.org/10.1038/s41591-018-0016-8openalex-snapshot
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
inferredcites →https://doi.org/10.1056/nejm199807023390104openalex-snapshot
Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma
inferredcites →https://doi.org/10.1056/nejmoa1707447openalex-snapshot
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1056/nejmoa1801445openalex-snapshot
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1056/nejmoa1804980openalex-snapshot
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1056/nejmra1706169openalex-snapshot
Chimeric Antigen Receptor Therapy
inferredcites →https://doi.org/10.1111/bjh.12846openalex-snapshot
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide ( RICER ) in first‐relapse/primary refractory diffuse large B‐cell lymphoma
inferredcites →https://doi.org/10.1111/bjh.14311openalex-snapshot
Next‐generation sequencing‐based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma
inferredcites →https://doi.org/10.1111/bjh.16756openalex-snapshot
Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-20-4929openalex-snapshot
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study
inferredcites →https://doi.org/10.1158/1538-7445.am2020-ct055openalex-snapshot
Abstract CT055: Phase 1/2 primary analysis of ZUMA-6: Axicabtagene ciloleucel (Axi-Cel) in combination With atezolizumab (Atezo) for the treatment of patients (Pts) with refractory diffuse large B cell lymphoma (DLBCL)
inferredcites →https://doi.org/10.1158/2159-8290.cd-18-0297openalex-snapshot
CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
inferredcites →https://doi.org/10.1159/000458147openalex-snapshot
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1182/blood-2005-04-1603openalex-snapshot
Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL
inferredcites →https://doi.org/10.1182/blood-2009-03-212191openalex-snapshot
Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
inferredcites →https://doi.org/10.1182/blood-2009-05-220095openalex-snapshot
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
inferredcites →https://doi.org/10.1182/blood-2010-03-276246openalex-snapshot
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
inferredcites →https://doi.org/10.1182/blood-2010-12-322362openalex-snapshot
Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
inferredcites →https://doi.org/10.1182/blood-2014-09-598763openalex-snapshot
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
inferredcites →https://doi.org/10.1182/blood-2016-01-643569openalex-snapshot
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
inferredcites →https://doi.org/10.1182/blood-2017-03-769620openalex-snapshot
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
inferredcites →https://doi.org/10.1182/blood-2017-07-793984openalex-snapshot
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma
inferredcites →https://doi.org/10.1182/blood-2018-99-112572openalex-snapshot
Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1182/blood-2018-99-119502openalex-snapshot
Sequential Anti-CD19 Directed Chimeric Antigen Receptor Modified T-Cell Therapy (CART19) and PD-1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
inferredcites →https://doi.org/10.1182/blood-2019-121521openalex-snapshot
Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
inferredcites →https://doi.org/10.1182/blood-2019-123742openalex-snapshot
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
inferredcites →https://doi.org/10.1182/blood-2019-126192openalex-snapshot
A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas
inferredcites →https://doi.org/10.1182/blood-2019-128475openalex-snapshot
Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results
inferredcites →https://doi.org/10.1182/blood-2019-129120openalex-snapshot
Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1182/blood-2020-133820openalex-snapshot
Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data
inferredcites →https://doi.org/10.1182/blood-2020-134449openalex-snapshot
Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)
inferredcites →https://doi.org/10.1182/blood-2020-134451openalex-snapshot
Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
inferredcites →https://doi.org/10.1182/blood-2020-134546openalex-snapshot
Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
inferredcites →https://doi.org/10.1182/blood-2020-135818openalex-snapshot
Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts
inferredcites →https://doi.org/10.1182/blood-2020-135988openalex-snapshot
ZUMA-19: A Phase 1/2 Multicenter Study of Lenzilumab Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) With Relapsed or Refractory Large B Cell Lymphoma (R/R LBCL)
inferredcites →https://doi.org/10.1182/blood-2020-136044openalex-snapshot
Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma
inferredcites →https://doi.org/10.1182/blood-2020-136067openalex-snapshot
Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
inferredcites →https://doi.org/10.1182/blood-2020-136295openalex-snapshot
Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in Combination with CHOP Confers High Response Rates in Patients with Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1182/blood-2020-136361openalex-snapshot
Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study
inferredcites →https://doi.org/10.1182/blood-2020-137328openalex-snapshot
Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression
inferredcites →https://doi.org/10.1182/blood-2020-138532openalex-snapshot
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen
inferredcites →https://doi.org/10.1182/blood-2020-138896openalex-snapshot
A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1182/blood-2020-139788openalex-snapshot
A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase
inferredcites →https://doi.org/10.1182/blood-2020-140752openalex-snapshot
Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study
inferredcites →https://doi.org/10.1182/blood-2020-141447openalex-snapshot
Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
inferredcites →https://doi.org/10.1182/blood.2019002600openalex-snapshot
The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH
inferredcites →https://doi.org/10.1182/blood.2019003277openalex-snapshot
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial
inferredcites →https://doi.org/10.1182/blood.2019003526openalex-snapshot
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
inferredcites →https://doi.org/10.1182/blood.2020006578openalex-snapshot
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
inferredcites →https://doi.org/10.1182/blood.2020007512openalex-snapshot
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
inferredcites →https://doi.org/10.1182/blood.v128.22.4639.4639openalex-snapshot
Lenalidomide Maintenance after Autologous Stem Cell Transplant in Patients with High-Risk Relapsed/Refractory Lymphomas Is Feasible and Compares Favorably to Historical Controls: Results of a Phase I/II Trial
inferredcites →https://doi.org/10.1182/bloodadvances.2019000600openalex-snapshot
T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma
inferredcites →https://doi.org/10.1182/bloodadvances.2019000784openalex-snapshot
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
inferredcites →https://doi.org/10.1182/bloodadvances.2019000875openalex-snapshot
Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
inferredcites →https://doi.org/10.1182/bloodadvances.2020002118openalex-snapshot
Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies
inferredcites →https://doi.org/10.1182/bloodadvances.2020002567openalex-snapshot
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial
inferredcites →https://doi.org/10.1182/bloodadvances.2020003001openalex-snapshot
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
inferredcites →https://doi.org/10.1182/bloodadvances.2020003092openalex-snapshot
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
inferredcites →https://doi.org/10.1182/bloodadvances.2023011369openalex-snapshot
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen
inferredcites →https://doi.org/10.1186/s13045-020-00900-7openalex-snapshot
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
inferredcites →https://doi.org/10.1200/jco.18.00766openalex-snapshot
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
inferredcites →https://doi.org/10.1200/jco.18.01583openalex-snapshot
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1200/jco.18.01994openalex-snapshot
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
inferredcites →https://doi.org/10.1200/jco.18.02403openalex-snapshot
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1200/jco.19.00172openalex-snapshot
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1200/jco.20.00999openalex-snapshot
Positron Emission Tomography–Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001
inferredcites →https://doi.org/10.1200/jco.2007.13.6929openalex-snapshot
Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014
inferredcites →https://doi.org/10.1200/jco.2009.26.2493openalex-snapshot
Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 + B-Cell Lymphoma in the Rituximab Era
inferredcites →https://doi.org/10.1200/jco.2009.26.3947openalex-snapshot
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
inferredcites →https://doi.org/10.1200/jco.2010.28.1618openalex-snapshot
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
inferredcites →https://doi.org/10.1200/jco.2011.35.4423openalex-snapshot
The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study
inferredcites →https://doi.org/10.1200/jco.2012.41.9416openalex-snapshot
Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma
inferredcites →https://doi.org/10.1200/jco.2013.51.5866openalex-snapshot
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
inferredcites →https://doi.org/10.1200/jco.2014.58.9846openalex-snapshot
Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)
inferredcites →https://doi.org/10.1200/jco.2014.60.2383openalex-snapshot
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
inferredcites →https://doi.org/10.1200/jco.2015.65.4582openalex-snapshot
Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736
inferredcites →https://doi.org/10.1200/jco.2016.70.0765openalex-snapshot
Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study
inferredcites →https://doi.org/10.1200/jco.2017.76.8093openalex-snapshot
Positron Emission Tomography–Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
inferredcites →https://doi.org/10.1200/jco.2018.78.5246openalex-snapshot
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
inferredcites →https://doi.org/10.1200/jco.2019.37.15_suppl.7552openalex-snapshot
Monitoring ctDNA in r/r DLBCL patients following the CAR T-cell therapy axicabtagene ciloleucel: Day 28 landmark analysis.
inferredcites →https://doi.org/10.1200/jco.2019.37.15_suppl.tps7571openalex-snapshot
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.8001openalex-snapshot
Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.8003openalex-snapshot
Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.
inferredcites →https://doi.org/10.1200/jco.2020.38.15_suppl.tps8073openalex-snapshot
Phase I/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network.
inferredcites →https://doi.org/10.1371/journal.pone.0183390openalex-snapshot
Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing
inferredcites →https://doi.org/10.14694/edbook_am.2015.35.e449openalex-snapshot
ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?
inferredcites →https://doi.org/10.3324/haematol.2016.142752openalex-snapshot
FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?
inferredcites →https://doi.org/10.3324/haematol.2019.238675openalex-snapshot
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
inferredcites →https://doi.org/10.4049/jimmunol.1103019openalex-snapshot
Chimeric Antigen Receptor T Cells Shape Myeloid Cell Function within the Tumor Microenvironment through IFN-γ and GM-CSF
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4824615openalex-extracted
Pet/Ct Cross-Modal Automatic Segmentation-Based Prognostic Assessment of Diffuse Large B-Cell Lymphoma Patients
inferred← citeshttps://doi.org/10.1002/ajh.27341openalex-snapshot
Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma
inferred← citeshttps://doi.org/10.1002/ams2.822openalex-snapshot
Aggressive diffuse large B‐cell lymphoma manifested by splenic rupture progressed 2 months after transverse myelitis: an autopsy case report
inferred← citeshttps://doi.org/10.1002/cam4.5957openalex-snapshot
A promising prognostic model for predicting survival of patients with HIV ‐related diffuse large B‐cell lymphoma in the cART era
inferred← citeshttps://doi.org/10.1002/cam4.70602openalex-snapshot
A Mitochondria‐Related Signature in Diffuse Large B‐Cell Lymphoma: Prognosis, Immune and Therapeutic Features
inferred← citeshttps://doi.org/10.1002/cam4.71531openalex-snapshot
Real‐World Outcomes of Polatuzumab Vedotin Plus R‐ CHP Versus R‐ CHOP ‐Based Regimens in Japanese Patients With Untreated Diffuse Large B‐Cell Lymphoma
inferred← citeshttps://doi.org/10.1002/cam4.7173openalex-snapshot
Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy
inferred← citeshttps://doi.org/10.1002/cbic.202500500openalex-snapshot
Screening the Irish Marine Biorepository Identifies a New Bryostatin Analog as Potent Inhibitor of Activated B‐Cells Diffuse Large B‐Cell Lymphoma
inferred← citeshttps://doi.org/10.1002/ctm2.70174openalex-snapshot
Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma
inferred← citeshttps://doi.org/10.1002/hon.3081openalex-snapshot
The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi
inferred← citeshttps://doi.org/10.1002/hon.3225openalex-snapshot
Expression of “DNA damage response” pathway genes in diffuse large B‐cell lymphoma: The potential for exploiting synthetic lethality
inferred← citeshttps://doi.org/10.1002/hon.70014openalex-snapshot
Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma
inferred← citeshttps://doi.org/10.1002/hon.70243openalex-snapshot
Metabolic Tumor Area: A Clinically Practical Prognostic Marker for Improved Risk Stratification in IPI Non‐High‐Risk DLBCL
inferred← citeshttps://doi.org/10.1002/jcla.70258openalex-snapshot
Assessment of Potential Sources of Variability on the Analytical Performance of a Circulating Tumor DNA Minimal Residual Disease Test for B‐Cell Lymphomas
inferred← citeshttps://doi.org/10.1002/jcp.31012openalex-snapshot
Upregulation of ENKD1 disrupts cellular homeostasis to promote lymphoma development
inferred← citeshttps://doi.org/10.1002/jev2.70309openalex-snapshot
Tumour‐Derived Extracellular Vesicles Induce Diffuse Large B‐Cell Lymphoma Progression Through Macrophage‐Mediated MDSC Accumulation
inferred← citeshttps://doi.org/10.1002/jha2.625openalex-snapshot
Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma
inferred← citeshttps://doi.org/10.1002/jha2.70256openalex-snapshot
A Real‐World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma in the United States
inferred← citeshttps://doi.org/10.1002/jha2.757openalex-snapshot
PET‐based radiomics signature can predict durable responses to CAR T‐cell therapy in patients with large B‐cell lymphoma
inferred← citeshttps://doi.org/10.1002/jmri.70524openalex-snapshot
Hyperpolarized 13 C Pyruvate MRI / MRS for Characterizing Splenic Metabolism in Advanced Diffuse Large B‐Cell Lymphoma: A Pilot Study
inferred← citeshttps://doi.org/10.1002/jmv.70621openalex-snapshot
Exploring the Potential Association of Infectious Mononucleosis With Diffuse Large B‐Cell Lymphoma: A Mendelian Randomization and miRNA Profiling Approach
inferred← citeshttps://doi.org/10.1002/jmv.71077openalex-snapshot
Clinical‐Stage Nanatinostat Triggers Productive Epstein‐Barr Virus Lytic Replication
inferred← citeshttps://doi.org/10.1007/978-3-031-47425-5_10openalex-snapshot
Graph-Based Multimodal Multi-lesion DLBCL Treatment Response Prediction from PET Images
inferred← citeshttps://doi.org/10.1007/978-3-032-04927-8_31openalex-snapshot
Lymphoma Prognosis with Lesion-Anatomy Context Fusion and Attention-Based Multi-lesion Aggregation
inferred← citeshttps://doi.org/10.1007/978-981-95-5171-2_17openalex-snapshot
Haematological Malignancies
inferred← citeshttps://doi.org/10.1007/s00018-023-05042-wopenalex-snapshot
Delineating the mechanism of fragility at BCL6 breakpoint region associated with translocations in diffuse large B cell lymphoma
inferred← citeshttps://doi.org/10.1007/s00262-025-04150-9openalex-snapshot
Spautin-1 inhibits the growth of diffuse large B-cell lymphoma by inducing mitochondrial damage-mediated PANoptosis and anti-tumor immunity
inferred← citeshttps://doi.org/10.1007/s00277-023-05157-xopenalex-snapshot
Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study
inferred← citeshttps://doi.org/10.1007/s00277-023-05303-5openalex-snapshot
Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis
inferred← citeshttps://doi.org/10.1007/s00277-024-05619-wopenalex-snapshot
Cause-specific mortality in a population-level cohort of diffuse large B-cell lymphoma following chemotherapy in the early 21st century
inferred← citeshttps://doi.org/10.1007/s00277-024-05831-8openalex-snapshot
Circulating subpopulations of non-cytotoxic ILCs in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s00277-024-05850-5openalex-snapshot
Quality of life assessment in diffuse large B-cell lymphoma (DLBCL) in REFLECT: a prospective, non-interventional, multicenter, German study, assessing Sandoz rituximab in combination with CHOP
inferred← citeshttps://doi.org/10.1007/s00277-025-06321-1openalex-snapshot
Identification of molecular clusters and a risk prognosis model for diffuse large B-cell lymphoma based on lactate metabolism-related genes
inferred← citeshttps://doi.org/10.1007/s00277-025-06508-6openalex-snapshot
Distinct structural and numerical chromosome abnormalities determine the MYC status in diffuse large B-Cell lymphoma and help differentiate from Burkitt lymphoma: a cytogenetic data analysis using unsupervised and AI-driven prediction models
inferred← citeshttps://doi.org/10.1007/s00277-025-06525-5openalex-snapshot
An international prognostic index to predict the early chemoimmunotherapy failure of diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s00277-025-06526-4openalex-snapshot
Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0–1 DLBCL patients
inferred← citeshttps://doi.org/10.1007/s00277-026-06798-4openalex-snapshot
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial
inferred← citeshttps://doi.org/10.1007/s00277-026-07068-zopenalex-snapshot
TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s00432-022-04179-8openalex-snapshot
Adherence to guidelines-recommended diagnostic testing was associated with overall survival in patients with diffuse large B-cell lymphoma after rituximab-based treatment: an observational cohort study
inferred← citeshttps://doi.org/10.1007/s10238-023-01018-zopenalex-snapshot
Identification of FAT4 as a positive prognostic biomarker in DLBCL by comprehensive genomic analysis
inferred← citeshttps://doi.org/10.1007/s10238-023-01127-9openalex-snapshot
A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s10238-023-01249-0openalex-snapshot
Prognostic impact of absolute peripheral blood NK cell count after four cycles of R-CHOP-like regimen treatment in patients with diffuse large B cell lymphoma
inferred← citeshttps://doi.org/10.1007/s10238-024-01326-yopenalex-snapshot
Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma
inferred← citeshttps://doi.org/10.1007/s10238-026-02174-8openalex-snapshot
Optimized interpretation of p53 immunohistochemistry for prediction of TP53 mutations and patient survival in DLBCL
inferred← citeshttps://doi.org/10.1007/s11033-022-08104-7openalex-snapshot
Fc receptor-like 1 (FCRL1) is a novel biomarker for prognosis and a possible therapeutic target in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s11094-025-03300-8openalex-snapshot
Aloe-Emodin Decreases the Hypoxia-Induced Radioresistance by Interacting with Hypoxiainducible Factor-1 α in SU-DHL-4 Cells
inferred← citeshttps://doi.org/10.1007/s11523-025-01133-9openalex-snapshot
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review
inferred← citeshttps://doi.org/10.1007/s11547-026-02233-wopenalex-snapshot
Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma
inferred← citeshttps://doi.org/10.1007/s11845-026-04385-0openalex-snapshot
Cyclophosphamide alters gut microbiota metabolism and structure in lymphoma-bearing mice: implications for dietary modulation
inferred← citeshttps://doi.org/10.1007/s12013-024-01637-7openalex-snapshot
A Novel Hypoxia-Featured Genes Prognostic Model for Identification of Hypoxia Subtypes in Diffuse Large B-Cell Lymphoma
inferred← citeshttps://doi.org/10.1007/s12032-025-03159-5openalex-snapshot
Fatty acid metabolic signature reveals FASN as an immunosuppressive factor in DLBCL tumor microenvironment
inferred← citeshttps://doi.org/10.1007/s12094-026-04336-2openalex-snapshot
Expression and diagnostic significance of plasma exosomal RNA in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s12185-023-03692-xopenalex-snapshot
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment
inferred← citeshttps://doi.org/10.1007/s12254-025-01041-8openalex-snapshot
Proposed prognostic score including circulating free DNA concentration in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1007/s12288-025-02125-5openalex-snapshot
Real Egyptian Single-Center Experience in Mantle Cell Lymphoma Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/s12672-025-03122-wopenalex-snapshot
Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism
inferred← citeshttps://doi.org/10.1007/s40487-024-00265-8openalex-snapshot
Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis
inferred← citeshttps://doi.org/10.1007/s40487-024-00282-7openalex-snapshot
Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma
inferred← citeshttps://doi.org/10.1007/s41870-024-02194-1openalex-snapshot
Architecting lymphoma fusion: PROMETHEE-II guided optimization of combination therapeutic synergy
inferred← citeshttps://doi.org/10.1007/s43152-025-00061-0openalex-snapshot
An Overview of Latest Developments in DLBCL its Pathogenesis, Immune Significance, Prognosis and Targets
inferred← citeshttps://doi.org/10.1007/s44313-026-00129-2openalex-snapshot
Exploring CD79b, LC3, and TERT expression in NON-GCB DLBCL: markers associated with Rituximab-Cyclophosphamide-Doxorubicin-Vincristin-Prednisone treatment response
inferred← citeshttps://doi.org/10.1016/b978-0-443-15717-2.00005-6openalex-snapshot
Hodgkin's Lymphoma
inferred← citeshttps://doi.org/10.1016/b978-0-443-15717-2.00013-5openalex-snapshot
The Role of MicroRNAs in Mature B-Cell Neoplasias Drug Resistance
inferred← citeshttps://doi.org/10.1016/b978-0-443-19200-5.00014-2openalex-snapshot
Therapeutic options for rituximab-resistant patients
inferred← citeshttps://doi.org/10.1016/j.ahj.2023.07.001openalex-snapshot
Importance of familial predisposition to heart failure to the risk of anthracycline-related cardiotoxicity: A nationwide study
inferred← citeshttps://doi.org/10.1016/j.ajoms.2025.10.014openalex-snapshot
CD20-negative diffuse large B-cell lymphoma occurring in the lower gingiva: A case report
inferred← citeshttps://doi.org/10.1016/j.anndiagpath.2022.152013openalex-snapshot
Diagnostic utility of the aberrant immunohistochemical expression of CD3 molecules for peripheral T-cell lymphomas
inferred← citeshttps://doi.org/10.1016/j.beha.2025.101637openalex-snapshot
Adoptive cellular therapies in non-Hodgkin lymphomas
inferred← citeshttps://doi.org/10.1016/j.bict.2026.100049openalex-snapshot
Lisocabtagene maraleucel outcome in large B-cell lymphoma associates with memory composition and mitochondrial fitness of T cells
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.116386openalex-snapshot
Ferroptosis mechanisms and its novel potential therapeutic targets for DLBCL
inferred← citeshttps://doi.org/10.1016/j.blre.2023.101136openalex-snapshot
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128825openalex-snapshot
Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.bneo.2026.100261openalex-snapshot
Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models
inferred← citeshttps://doi.org/10.1016/j.bspc.2022.103728openalex-snapshot
Deep discriminative learning model with calibrated attention map for the automated diagnosis of diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.canlet.2022.215678openalex-snapshot
MORTALIN-Ca2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.canlet.2024.216978openalex-snapshot
Targeting the ubiquitin pathway in lymphoid malignancies
inferred← citeshttps://doi.org/10.1016/j.cellsig.2025.112155openalex-snapshot
KIF2C regulates macrophage M2 polarization and DLBCL progression by regulating the STAT3/IL-10 axis
inferred← citeshttps://doi.org/10.1016/j.clml.2025.10.010openalex-snapshot
Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis
inferred← citeshttps://doi.org/10.1016/j.colsurfb.2025.115271openalex-snapshot
Dual-targeted exosome nanoplatform co-delivering doxorubicin and Fuzi Lizhong Tang bioactives for synergistic DLBCL therapy and chemotherapy-induced diarrhea management
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2022.105565openalex-snapshot
A bibliometric analysis of diffuse large B-cell lymphoma research from 2001 to 2020
inferred← citeshttps://doi.org/10.1016/j.compbiomed.2024.107978openalex-snapshot
HoLy-Net: Segmentation of histological images of diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.compmedimag.2024.102481openalex-snapshot
PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction
inferred← citeshttps://doi.org/10.1016/j.crad.2023.01.010openalex-snapshot
The prognostic value of splenic abnormalities in pretreatment 18F-FDG PET/CT in patients with complete response diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.ctarc.2026.101144openalex-snapshot
From pixels to prognosis: A QUADAS-2–Guided systematic review and meta-analysis of deep learning segmentation for DLBCL in PET and PET/CT
inferred← citeshttps://doi.org/10.1016/j.drudis.2023.103612openalex-snapshot
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases
inferred← citeshttps://doi.org/10.1016/j.exphem.2023.04.002openalex-snapshot
Platycodin D induces proliferation inhibition and mitochondrial apoptosis in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.exphem.2024.104638openalex-snapshot
Downregulation of autophagy is associated with poor clinical outcome after immunochemotherapy in patients with diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.gene.2024.148320openalex-snapshot
Anthropometric indicators may explain the high incidence of follicular lymphoma in Europeans: Results from a bidirectional two-sample two-step Mendelian randomisation
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e28584openalex-snapshot
Artesunate induces ferroptosis by regulating MT1G and has an additive effect with doxorubicin in diffuse large B-cell lymphoma cells
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2025.139910openalex-snapshot
RETRACTED: Protein molecular structures of USP53, NPY2R, and DCTN1-AS1 and impact on tumors: Analysis of prognostic biomarkers for diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.ijscr.2023.108327openalex-snapshot
Navigating treatment options for sacral spine lymphoma
inferred← citeshttps://doi.org/10.1016/j.ijscr.2023.108861openalex-snapshot
Atypical diffuse large B-cell lymphoma, primary splenic lymphoma variant; a case report
inferred← citeshttps://doi.org/10.1016/j.insi.2025.100047openalex-snapshot
Novel design and in silico optimization of 5-azaquinazoline-based IRAK4 inhibitors using qsar, docking, pharmacokinetics, and molecular dynamics for diffuse large B-Cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.111125openalex-snapshot
Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.113319openalex-snapshot
Single-cell sequencing in diffuse large B-cell lymphoma: C1qC is a potential tumor-promoting factor
inferred← citeshttps://doi.org/10.1016/j.intimp.2025.114578openalex-snapshot
Rituximab-Chidamide combination chemotherapy enhances autophagy to overcome drug resistance in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.jpet.2026.105012openalex-snapshot
Shiheleucel, an allogeneic natural killer cell product expanded under chemically defined conditions, in combination with rituximab-based chemotherapy in relapsed/refractory diffuse large B-cell lymphoma: An exploratory clinical study
inferred← citeshttps://doi.org/10.1016/j.jtct.2023.04.003openalex-snapshot
Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
inferred← citeshttps://doi.org/10.1016/j.medcle.2021.09.011openalex-snapshot
Estimates of the incidence of hematological neoplasms in Spain, 2021: Study of the Spanish Network of Cancer Registries (REDECAN)
inferred← citeshttps://doi.org/10.1016/j.medcli.2021.09.035openalex-snapshot
Estimaciones de la incidencia de las neoplasias hematológicas en España, 2021: estudio de la Red Española de Registros de Cáncer (REDECAN)
inferred← citeshttps://doi.org/10.1016/j.mpdhp.2024.05.007openalex-snapshot
Renamed, not tamed: angioimmunoblastic T-cell lymphoma, a diagnostic troublemaker
inferred← citeshttps://doi.org/10.1016/j.mtbio.2025.102177openalex-snapshot
Sophora flavescens-derived extracellular vesicles loaded with oncolytic vaccinia virus/IR1061 for NIR-II photoacoustic imaging guided multimodal treatment of diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.omta.2026.201686openalex-snapshot
Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies
inferred← citeshttps://doi.org/10.1016/j.pathol.2025.04.007openalex-snapshot
High PHD finger protein 19 expression predicts inferior prognosis in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.prp.2025.156036openalex-snapshot
B-cell lymphoma: Advances in pathogenesis, diagnosis, and targeted therapies
inferred← citeshttps://doi.org/10.1016/j.radonc.2023.109902openalex-snapshot
Decreased lymphoma-related deaths and improved long-term relative survival with radiotherapy for early-stage diffuse large B-cell lymphoma in the rituximab era
inferred← citeshttps://doi.org/10.1016/j.redox.2025.103878openalex-snapshot
NFS1, together with FXN, protects cells from ferroptosis and DNA damage in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/j.saa.2023.123795openalex-snapshot
Automatic subtyping of Diffuse Large B-cell Lymphomas (DLBCL): Raman-based genetic and metabolic classification
inferred← citeshttps://doi.org/10.1016/j.taap.2024.117103openalex-snapshot
Wogonin induces mitochondrial apoptosis and synergizes with venetoclax in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1016/s0140-6736(24)01774-4openalex-snapshot
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
inferred← citeshttps://doi.org/10.1016/s1875-5364(25)60873-9openalex-snapshot
(+)-Strebloside induces Non-Hodgkin lymphoma cell death through the STEAP3-Mediated Ferroptosis and MAPK pathway
inferred← citeshttps://doi.org/10.1038/s41375-022-01769-wopenalex-snapshot
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL
inferred← citeshttps://doi.org/10.1038/s41375-025-02688-2openalex-snapshot
Integration of [18F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1038/s41375-026-02948-9openalex-snapshot
Targeting of ibrutinib resistance–driving pathways by miR-28 in ABC-DLBCL
inferred← citeshttps://doi.org/10.1038/s41392-025-02316-6openalex-snapshot
Genetic subtype-guided immunochemotherapy in relapsed and refractory diffuse large B cell lymphoma: a phase 2 investigator-initiated nonrandomized clinical trial (GUIDANCE-06)
inferred← citeshttps://doi.org/10.1038/s41401-024-01311-xopenalex-snapshot
Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas
inferred← citeshttps://doi.org/10.1038/s41408-025-01412-8openalex-snapshot
Real-world treatment patterns and clinical outcomes among patients with diffuse large B-cell lymphoma in a US healthcare claims database
inferred← citeshttps://doi.org/10.1038/s41419-023-06178-0openalex-snapshot
miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication
inferred← citeshttps://doi.org/10.1038/s41419-023-06299-6openalex-snapshot
Characterizing influence of rCHOP treatment on diffuse large B-cell lymphoma microenvironment through in vitro microfluidic spheroid model
inferred← citeshttps://doi.org/10.1038/s41419-024-06941-xopenalex-snapshot
Rupatadine-inhibited OTUD3 promotes DLBCL progression and immune evasion through deubiquitinating MYL12A and PD-L1
inferred← citeshttps://doi.org/10.1038/s41419-025-07822-7openalex-snapshot
Artesunate induces ferroptosis in diffuse large B-cell lymphoma cells by targeting PRDX1 and PRDX2
inferred← citeshttps://doi.org/10.1038/s41598-024-79791-4openalex-snapshot
Mendelian randomization analysis reveals causal effects of inflammatory bowel disease and autoimmune hyperthyroidism on diffuse large B-cell lymphoma risk
inferred← citeshttps://doi.org/10.1038/s41598-025-23159-9openalex-snapshot
Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy
inferred← citeshttps://doi.org/10.1038/s41598-026-44677-0openalex-snapshot
Peripheral blood mononuclear cell gene expression signatures predict long-term survivorship in canine DLBCL
inferred← citeshttps://doi.org/10.1038/s43018-025-00921-6openalex-snapshot
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial
inferred← citeshttps://doi.org/10.1038/s43856-024-00540-9openalex-snapshot
Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers
inferred← citeshttps://doi.org/10.1038/s44276-025-00147-0openalex-snapshot
Deep learning-based interpretable prediction of recurrence of diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1055/a-2277-0672openalex-snapshot
Finding the needle in a haystack: single-balloon enteroscopy to diagnose diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1055/s-0041-1735392openalex-snapshot
Molecular Classification of Diffuse Large B-Cell Lymphoma
inferred← citeshttps://doi.org/10.1055/s-0043-1768567openalex-snapshot
What Does an Adult Hemato-Oncology Physician Expect from a Hematopathologist?
inferred← citeshttps://doi.org/10.1055/s-0044-1791800openalex-snapshot
Polatuzumab Vedotin for Diffuse Large B-Cell Lymphoma: Innovation's Allure versus a Time-Honored Tradition
inferred← citeshttps://doi.org/10.1055/s-0046-1827827openalex-snapshot
Tuberculosis Mimicking Relapse of Hodgkin's Lymphoma in an Adolescent: A Diagnostic Pitfall in Tuberculosis-Endemic Regions
inferred← citeshttps://doi.org/10.1080/07357907.2024.2405184openalex-snapshot
Identification of Immune-Related Gene Pair Signature to Predict Prognosis of Diffuse Large B-Cell Lymphoma Based on Bioinformatics Analyses
inferred← citeshttps://doi.org/10.1080/10428194.2021.2018580openalex-snapshot
Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients’ outcome
inferred← citeshttps://doi.org/10.1080/10428194.2021.2020781openalex-snapshot
Specific TCR V–J gene segment recombinations leading to the identification pan-V–J CDR3s associated with survival distinctions: diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1080/10428194.2022.2081325openalex-snapshot
Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study
inferred← citeshttps://doi.org/10.1080/10428194.2022.2147395openalex-snapshot
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort study using CMS 100% Medicare claims database
inferred← citeshttps://doi.org/10.1080/10428194.2023.2298705openalex-snapshot
Challenges identifying DLBCL patients with poor outcomes to upfront chemoimmunotherapy and its impact on frontline clinical trials
inferred← citeshttps://doi.org/10.1080/10428194.2025.2504719openalex-snapshot
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma
inferred← citeshttps://doi.org/10.1080/10428194.2025.2604300openalex-snapshot
Real-world treatment patterns and characteristics of patients with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of US commercial and Medicare claims (2017–2024)
inferred← citeshttps://doi.org/10.1080/10428194.2026.2721032openalex-snapshot
CD74 in hematological malignancies: from MHC chaperone to therapeutic target
inferred← citeshttps://doi.org/10.1080/14712598.2025.2479631openalex-snapshot
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-Hodgkin lymphoma
inferred← citeshttps://doi.org/10.1080/14737140.2024.2362186openalex-snapshot
Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma
inferred← citeshttps://doi.org/10.1080/16078454.2024.2445395openalex-snapshot
Factors affecting refractoriness or recurrence in diffuse large B-cell lymphoma: development and validation of a novel predictive nomogram
inferred← citeshttps://doi.org/10.1080/16078454.2026.2619209openalex-snapshot
XPO1 Inhibition enhances sensitivity to platinum-based chemotherapy in germinal-center B-cell-like-DLBCL cells
inferred← citeshttps://doi.org/10.1080/29947448.2026.2654916openalex-snapshot
Vascular phenotype as predictive markers of CAR-T cell therapy response in patients with diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1088/2057-1976/ae06abopenalex-snapshot
Automated quantification and feature extraction of nuclei in diffuse large B-cell lymphoma using advanced imaging techniques
inferred← citeshttps://doi.org/10.1093/jamia/ocae231openalex-snapshot
CACER: Clinical concept Annotations for Cancer Events and Relations
inferred← citeshttps://doi.org/10.1093/jn/nxac122openalex-snapshot
Association between Meat, Fish, and Fatty Acid Intake and Non-Hodgkin Lymphoma Incidence: The Japan Public Health Center–Based Prospective Study
inferred← citeshttps://doi.org/10.1093/narcan/zcaf017openalex-snapshot
Leveraging the interconnected unfolded protein response and NLRP3 inflammasome pathways to reactivate Epstein–Barr virus in diffuse large B-cell lymphomas
inferred← citeshttps://doi.org/10.1097/bs9.0000000000000179openalex-snapshot
Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia
inferred← citeshttps://doi.org/10.1097/cad.0000000000001774openalex-snapshot
Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series
inferred← citeshttps://doi.org/10.1097/cm9.0000000000003634openalex-snapshot
Erianin induces GSDMD-dependent pyroptosis and synergistically enhances doxorubicin efficacy via the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1097/dad.0000000000002576openalex-snapshot
Cutaneous Involvement by Diffuse Large B-Cell Lymphoma With Dual B-Cell and T-Cell Clonality and Heavy Admixed T-Cell Infiltrate: Answer
inferred← citeshttps://doi.org/10.1097/md.0000000000043959openalex-snapshot
Isolated primary diffuse large B-cell lymphoma in thumb, the first case in medical literature: Case report and literature review
inferred← citeshttps://doi.org/10.1097/mnm.0000000000001925openalex-snapshot
PET/computed tomography radiomics combined with clinical features in predicting sarcopenia and prognosis of diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1097/pai.0000000000001208openalex-snapshot
Expression and Clinical Significance of Ki-67, CD10, BCL6, MUM1, c-MYC, and EBV in Diffuse Large B Cell Lymphoma Patients
inferred← citeshttps://doi.org/10.1097/qad.0000000000004197openalex-snapshot
A promising prognostic model for patients with AIDS-related lymphoma in the combination antiretroviral therapy era
inferred← citeshttps://doi.org/10.1111/ajco.14208openalex-snapshot
A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia
inferred← citeshttps://doi.org/10.1111/bjh.19699openalex-snapshot
Prognostic stratification in DLBCL patients with aberrant MYC gene
inferred← citeshttps://doi.org/10.1111/cas.15055openalex-snapshot
Pyruvate dehydrogenase kinase 4‐mediated metabolic reprogramming is involved in rituximab resistance in diffuse large B‐cell lymphoma by affecting the expression of MS4A1/CD20
inferred← citeshttps://doi.org/10.1111/cas.15296openalex-snapshot
Downregulation of miR‐26 promotes invasion and metastasis via targeting interleukin‐22 in cutaneous T‐cell lymphoma
inferred← citeshttps://doi.org/10.1111/cas.70554openalex-snapshot
A Novel Plasma Biomarker hsa_circ_0080018 Drives DLBCL Progression via M2 Polarization of Tumor‐Associated Macrophages
inferred← citeshttps://doi.org/10.1111/echo.70339openalex-snapshot
Left Atrial Function in Patients With Diffuse Large B‐Cell Lymphoma Treated With R‐CHOP Chemotherapy Regimen: A Speckle Tracking Echocardiographic Study
inferred← citeshttps://doi.org/10.1111/jgh.16725openalex-snapshot
Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B
inferred← citeshttps://doi.org/10.1136/bmjopen-2022-068943openalex-snapshot
Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
inferred← citeshttps://doi.org/10.1146/annurev-cancerbio-061824-105806openalex-snapshot
Development of PROTAC Degrader Drugs for Cancer
inferred← citeshttps://doi.org/10.1155/2022/3222253openalex-snapshot
Bioinformatics Analysis of miRNAs Targeting TRAF5 in DLBCL Involving in NF-κB Signaling Pathway and Affecting the Apoptosis and Signal Transduction
inferred← citeshttps://doi.org/10.1155/2022/4379556openalex-snapshot
[Retracted] Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B‐Cell Lymphoma
inferred← citeshttps://doi.org/10.1155/2022/5618290openalex-snapshot
Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta‐Analysis
inferred← citeshttps://doi.org/10.1155/2023/1388041openalex-snapshot
IGFBP3 Enhances Treatment Outcome and Predicts Favorable Prognosis in ABC-DLBCL
inferred← citeshttps://doi.org/10.1155/2024/3091760openalex-snapshot
B‐Cell Chronic Lymphocytic Leukemia and B‐Cell Lymphomas: The Key Role of Micro and Long Noncoding RNAs
inferred← citeshttps://doi.org/10.1155/jcpt/1766313openalex-snapshot
Systemic Cancer Therapy‐Related Adverse Drug Reactions and Associated Clinical Outcomes Among Lymphoma Patients at Kenyatta National Hospital
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-22-1682openalex-snapshot
Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases
inferred← citeshttps://doi.org/10.1158/2643-3230.bcd-25-0059openalex-snapshot
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
inferred← citeshttps://doi.org/10.1159/000549477openalex-snapshot
Real-World Comparative Analysis of Polatuzumab Vedotin-Based Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone versus Standard Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched…
inferred← citeshttps://doi.org/10.11606/t.5.2024.tde-22052024-140427openalex-snapshot
O efeito da ivabradina na prevenção da disfunção cardiovascular relacionada à antraciclina: estudo clínico randomizado
inferred← citeshttps://doi.org/10.1161/circimaging.122.014829openalex-snapshot
Cardiovascular Risk Stratification by Automatic Coronary Artery Calcium Scoring on Pretreatment Chest Computed Tomography in Diffuse Large B-Cell Lymphoma Receiving Anthracycline-Based Chemotherapy: A Multicenter Study
inferred← citeshttps://doi.org/10.1172/jci179703openalex-snapshot
An epigenetic pathway regulates MHC-II expression and function in B cell lymphoma models
inferred← citeshttps://doi.org/10.1177/00045632241297873openalex-snapshot
Usefulness of the 3-hydroxykynurenine/kynurenic acid ratio as a diagnostic biomarker for diffuse larger B-cell lymphoma
inferred← citeshttps://doi.org/10.1177/03946320241292665openalex-snapshot
Plasma long non-coding RNAs as biomarkers for bone marrow infiltration and stage in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1177/09612033221114578openalex-snapshot
Exploration of the molecular mechanisms, shared gene signatures, and MicroRNAs between systemic lupus erythematosus and diffuse large B cell lymphoma by bioinformatics analysis
inferred← citeshttps://doi.org/10.1177/11795549231203142openalex-snapshot
Clinical Features and Outcomes of Primary Breast Diffuse Large B-Cell Lymphoma: A Matched-Pair Study
inferred← citeshttps://doi.org/10.1177/18758592251322040openalex-snapshot
Internalization of extracellular double-stranded DNA as a potential marker of cancer stem cells in Epstein–Barr virus-induced B-cell lymphoma
inferred← citeshttps://doi.org/10.1177/23247096251325409openalex-snapshot
Concomitant Polycythemia Vera and Primary Splenic Diffuse Large B-Cell Lymphoma Complicated by Gastrosplenic Fistula: A Case Report
inferred← citeshttps://doi.org/10.1177/2515690x231198315openalex-snapshot
Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression
inferred← citeshttps://doi.org/10.1182/blood.2022017734openalex-snapshot
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
inferred← citeshttps://doi.org/10.1182/bloodadvances.2022009260openalex-snapshot
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1182/bloodadvances.2024015469openalex-snapshot
Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1182/bloodadvances.2026019764openalex-snapshot
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO
inferred← citeshttps://doi.org/10.1186/s12865-026-00819-7openalex-snapshot
Prognostic application regarding PILE score and the pan-immune-inflammation value in diffuse large B-Cell Lymphoma
inferred← citeshttps://doi.org/10.1186/s12880-026-02552-4openalex-snapshot
18F-FDG PET/CT radiomics combined with double-expressor status enhances prognostication and high-risk stratification in DLBCL
inferred← citeshttps://doi.org/10.1186/s12885-023-11186-6openalex-snapshot
CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1186/s12885-024-11837-2openalex-snapshot
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era
inferred← citeshttps://doi.org/10.1186/s12885-024-11876-9openalex-snapshot
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
inferred← citeshttps://doi.org/10.1186/s12885-025-14142-8openalex-snapshot
Abnormal proportions and functions of myeloid-derived suppressor cells in peripheral blood of patients with diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1186/s12885-025-15149-xopenalex-snapshot
Tumor metabolic heterogeneity based on 18F-FDG PET/CT is a predictor of outcome in diffuse large B-cell lymphoma
inferred← citeshttps://doi.org/10.1186/s12885-026-15868-9openalex-snapshot
High-risk subgroup and associated genes identified by next generation sequencing in diffuse large B cell lymphoma
inferred← citeshttps://doi.org/10.1186/s12963-025-00415-8openalex-snapshot
Evaluation and forecasting methods to estimate number of patients with non-Hodgkin lymphoma: a systematic literature review
inferred← citeshttps://doi.org/10.1186/s12964-025-02617-xopenalex-snapshot
USP5 inhibition stimulates immunogenic ferroptosis that enhances immunotherapy in diffuse large B-cell lymphoma
showing the first 200 of 392 · page through all 392
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.